Famotidine

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 1938 Experts worldwide ranked by ideXlab platform

David A Tuveson - One of the best experts on this subject based on the ideXlab platform.

  • abstract s04 01 Famotidine use and quantitative symptom tracking for covid 19 in nonhospitalized patients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality, and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist Famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidine orally. Design: Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews. Based on an NIH-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scale modeled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalized symptom scores were statistically compared. Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified. The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to 21 days). Famotidine was well tolerated. All patients reported marked improvements of disease-related symptoms after starting Famotidine. The combined symptom score improved significantly within 24 hours of starting Famotidine and peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased. Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19. A blinded outpatient trial is planned. The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19. Citation Format: Tobias Janowitz, Eva C. Gablenz, David J. Pattinson, Timothy C. Wang, Joseph Conigliaro, Kevin J. Tracey, David A. Tuveson. Famotidine use and quantitative symptom tracking for COVID-19 in nonhospitalized patients: A case series [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr S04-01.

  • Famotidine use and quantitative symptom tracking for covid 19 in non hospitalised patients a case series
    Gut, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist Famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient reported outcome measures in non-hospitalised patients with COVID-19 who self-administered high-dose Famotidine orally. Design Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, Famotidine use, drug-related side effects, temperature measurements, oxygen saturations and symptom scores were obtained using questionnaires and telephone interviews. Based on a National Institute of Health (NIH)-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches and anosmia) and general unwellness on a four-point ordinal scale modelled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalised symptom scores were statistically compared. Results Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified. The most frequently used Famotidine regimen was 80 mg three times daily (n=6) for a median of 11 days (range: 5–21 days). Famotidine was well tolerated. All patients reported marked improvements of disease related symptoms after starting Famotidine. The combined symptom score improved significantly within 24 hours of starting Famotidine and peripheral oxygen saturation (n=2) and device recorded activity (n=1) increased. Conclusions The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.

  • Famotidine use and quantitative symptom tracking for covid 19 in nonhospitalized patients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reducemorbidity, mortality, and spread of the disease are an urgent global need The over-the-counter histamine-2 receptorantagonist Famotidine is a putative therapy for COVID-19 We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidineorally Design: Patients were enrolled consecutively after signing written informed consent Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews Based on an NIH-endorsedProtocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms(cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scalemodeled on performance status scoring All data are reported at the patient level Longitudinal combined normalizedsymptom scores were statistically compared Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to21 days) Famotidine was well tolerated All patients reported marked improvements of disease-related symptomsafter starting Famotidine The combined symptom score improved significantly within 24 hours of starting Famotidineand peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19 A blinded outpatient trial isplanned The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19

  • Famotidine use and quantitativesymptom tracking for covid 19 in nonhospitalizedpatients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reducemorbidity, mortality, and spread of the disease are an urgent global need The over-the-counter histamine-2 receptorantagonist Famotidine is a putative therapy for COVID-19 We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidineorally Design: Patients were enrolled consecutively after signing written informed consent Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews Based on an NIH-endorsedProtocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms(cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scalemodeled on performance status scoring All data are reported at the patient level Longitudinal combined normalizedsymptom scores were statistically compared Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to21 days) Famotidine was well tolerated All patients reported marked improvements of disease-related symptomsafter starting Famotidine The combined symptom score improved significantly within 24 hours of starting Famotidineand peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19 A blinded outpatient trial isplanned The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19

Tobias Janowitz - One of the best experts on this subject based on the ideXlab platform.

  • abstract s04 01 Famotidine use and quantitative symptom tracking for covid 19 in nonhospitalized patients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality, and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist Famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidine orally. Design: Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews. Based on an NIH-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scale modeled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalized symptom scores were statistically compared. Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified. The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to 21 days). Famotidine was well tolerated. All patients reported marked improvements of disease-related symptoms after starting Famotidine. The combined symptom score improved significantly within 24 hours of starting Famotidine and peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased. Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19. A blinded outpatient trial is planned. The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19. Citation Format: Tobias Janowitz, Eva C. Gablenz, David J. Pattinson, Timothy C. Wang, Joseph Conigliaro, Kevin J. Tracey, David A. Tuveson. Famotidine use and quantitative symptom tracking for COVID-19 in nonhospitalized patients: A case series [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr S04-01.

  • Famotidine use and quantitative symptom tracking for covid 19 in non hospitalised patients a case series
    Gut, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist Famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient reported outcome measures in non-hospitalised patients with COVID-19 who self-administered high-dose Famotidine orally. Design Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, Famotidine use, drug-related side effects, temperature measurements, oxygen saturations and symptom scores were obtained using questionnaires and telephone interviews. Based on a National Institute of Health (NIH)-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches and anosmia) and general unwellness on a four-point ordinal scale modelled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalised symptom scores were statistically compared. Results Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified. The most frequently used Famotidine regimen was 80 mg three times daily (n=6) for a median of 11 days (range: 5–21 days). Famotidine was well tolerated. All patients reported marked improvements of disease related symptoms after starting Famotidine. The combined symptom score improved significantly within 24 hours of starting Famotidine and peripheral oxygen saturation (n=2) and device recorded activity (n=1) increased. Conclusions The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.

  • Famotidine use and quantitative symptom tracking for covid 19 in nonhospitalized patients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reducemorbidity, mortality, and spread of the disease are an urgent global need The over-the-counter histamine-2 receptorantagonist Famotidine is a putative therapy for COVID-19 We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidineorally Design: Patients were enrolled consecutively after signing written informed consent Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews Based on an NIH-endorsedProtocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms(cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scalemodeled on performance status scoring All data are reported at the patient level Longitudinal combined normalizedsymptom scores were statistically compared Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to21 days) Famotidine was well tolerated All patients reported marked improvements of disease-related symptomsafter starting Famotidine The combined symptom score improved significantly within 24 hours of starting Famotidineand peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19 A blinded outpatient trial isplanned The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19

  • Famotidine use and quantitativesymptom tracking for covid 19 in nonhospitalizedpatients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reducemorbidity, mortality, and spread of the disease are an urgent global need The over-the-counter histamine-2 receptorantagonist Famotidine is a putative therapy for COVID-19 We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidineorally Design: Patients were enrolled consecutively after signing written informed consent Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews Based on an NIH-endorsedProtocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms(cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scalemodeled on performance status scoring All data are reported at the patient level Longitudinal combined normalizedsymptom scores were statistically compared Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to21 days) Famotidine was well tolerated All patients reported marked improvements of disease-related symptomsafter starting Famotidine The combined symptom score improved significantly within 24 hours of starting Famotidineand peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19 A blinded outpatient trial isplanned The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19

Eva C Gablenz - One of the best experts on this subject based on the ideXlab platform.

  • abstract s04 01 Famotidine use and quantitative symptom tracking for covid 19 in nonhospitalized patients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality, and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist Famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidine orally. Design: Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews. Based on an NIH-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scale modeled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalized symptom scores were statistically compared. Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified. The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to 21 days). Famotidine was well tolerated. All patients reported marked improvements of disease-related symptoms after starting Famotidine. The combined symptom score improved significantly within 24 hours of starting Famotidine and peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased. Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19. A blinded outpatient trial is planned. The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19. Citation Format: Tobias Janowitz, Eva C. Gablenz, David J. Pattinson, Timothy C. Wang, Joseph Conigliaro, Kevin J. Tracey, David A. Tuveson. Famotidine use and quantitative symptom tracking for COVID-19 in nonhospitalized patients: A case series [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr S04-01.

  • Famotidine use and quantitative symptom tracking for covid 19 in non hospitalised patients a case series
    Gut, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist Famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient reported outcome measures in non-hospitalised patients with COVID-19 who self-administered high-dose Famotidine orally. Design Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, Famotidine use, drug-related side effects, temperature measurements, oxygen saturations and symptom scores were obtained using questionnaires and telephone interviews. Based on a National Institute of Health (NIH)-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches and anosmia) and general unwellness on a four-point ordinal scale modelled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalised symptom scores were statistically compared. Results Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified. The most frequently used Famotidine regimen was 80 mg three times daily (n=6) for a median of 11 days (range: 5–21 days). Famotidine was well tolerated. All patients reported marked improvements of disease related symptoms after starting Famotidine. The combined symptom score improved significantly within 24 hours of starting Famotidine and peripheral oxygen saturation (n=2) and device recorded activity (n=1) increased. Conclusions The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.

  • Famotidine use and quantitative symptom tracking for covid 19 in nonhospitalized patients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reducemorbidity, mortality, and spread of the disease are an urgent global need The over-the-counter histamine-2 receptorantagonist Famotidine is a putative therapy for COVID-19 We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidineorally Design: Patients were enrolled consecutively after signing written informed consent Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews Based on an NIH-endorsedProtocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms(cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scalemodeled on performance status scoring All data are reported at the patient level Longitudinal combined normalizedsymptom scores were statistically compared Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to21 days) Famotidine was well tolerated All patients reported marked improvements of disease-related symptomsafter starting Famotidine The combined symptom score improved significantly within 24 hours of starting Famotidineand peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19 A blinded outpatient trial isplanned The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19

  • Famotidine use and quantitativesymptom tracking for covid 19 in nonhospitalizedpatients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reducemorbidity, mortality, and spread of the disease are an urgent global need The over-the-counter histamine-2 receptorantagonist Famotidine is a putative therapy for COVID-19 We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidineorally Design: Patients were enrolled consecutively after signing written informed consent Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews Based on an NIH-endorsedProtocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms(cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scalemodeled on performance status scoring All data are reported at the patient level Longitudinal combined normalizedsymptom scores were statistically compared Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to21 days) Famotidine was well tolerated All patients reported marked improvements of disease-related symptomsafter starting Famotidine The combined symptom score improved significantly within 24 hours of starting Famotidineand peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19 A blinded outpatient trial isplanned The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19

Timothy C Wang - One of the best experts on this subject based on the ideXlab platform.

  • abstract s04 01 Famotidine use and quantitative symptom tracking for covid 19 in nonhospitalized patients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality, and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist Famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidine orally. Design: Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews. Based on an NIH-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scale modeled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalized symptom scores were statistically compared. Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified. The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to 21 days). Famotidine was well tolerated. All patients reported marked improvements of disease-related symptoms after starting Famotidine. The combined symptom score improved significantly within 24 hours of starting Famotidine and peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased. Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19. A blinded outpatient trial is planned. The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19. Citation Format: Tobias Janowitz, Eva C. Gablenz, David J. Pattinson, Timothy C. Wang, Joseph Conigliaro, Kevin J. Tracey, David A. Tuveson. Famotidine use and quantitative symptom tracking for COVID-19 in nonhospitalized patients: A case series [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr S04-01.

  • Famotidine use and quantitative symptom tracking for covid 19 in non hospitalised patients a case series
    Gut, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist Famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient reported outcome measures in non-hospitalised patients with COVID-19 who self-administered high-dose Famotidine orally. Design Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, Famotidine use, drug-related side effects, temperature measurements, oxygen saturations and symptom scores were obtained using questionnaires and telephone interviews. Based on a National Institute of Health (NIH)-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches and anosmia) and general unwellness on a four-point ordinal scale modelled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalised symptom scores were statistically compared. Results Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified. The most frequently used Famotidine regimen was 80 mg three times daily (n=6) for a median of 11 days (range: 5–21 days). Famotidine was well tolerated. All patients reported marked improvements of disease related symptoms after starting Famotidine. The combined symptom score improved significantly within 24 hours of starting Famotidine and peripheral oxygen saturation (n=2) and device recorded activity (n=1) increased. Conclusions The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.

  • Famotidine use and quantitative symptom tracking for covid 19 in nonhospitalized patients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reducemorbidity, mortality, and spread of the disease are an urgent global need The over-the-counter histamine-2 receptorantagonist Famotidine is a putative therapy for COVID-19 We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidineorally Design: Patients were enrolled consecutively after signing written informed consent Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews Based on an NIH-endorsedProtocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms(cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scalemodeled on performance status scoring All data are reported at the patient level Longitudinal combined normalizedsymptom scores were statistically compared Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to21 days) Famotidine was well tolerated All patients reported marked improvements of disease-related symptomsafter starting Famotidine The combined symptom score improved significantly within 24 hours of starting Famotidineand peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19 A blinded outpatient trial isplanned The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19

  • Famotidine use and quantitativesymptom tracking for covid 19 in nonhospitalizedpatients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reducemorbidity, mortality, and spread of the disease are an urgent global need The over-the-counter histamine-2 receptorantagonist Famotidine is a putative therapy for COVID-19 We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidineorally Design: Patients were enrolled consecutively after signing written informed consent Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews Based on an NIH-endorsedProtocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms(cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scalemodeled on performance status scoring All data are reported at the patient level Longitudinal combined normalizedsymptom scores were statistically compared Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to21 days) Famotidine was well tolerated All patients reported marked improvements of disease-related symptomsafter starting Famotidine The combined symptom score improved significantly within 24 hours of starting Famotidineand peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19 A blinded outpatient trial isplanned The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19

Kevin J Tracey - One of the best experts on this subject based on the ideXlab platform.

  • abstract s04 01 Famotidine use and quantitative symptom tracking for covid 19 in nonhospitalized patients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality, and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist Famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidine orally. Design: Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews. Based on an NIH-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scale modeled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalized symptom scores were statistically compared. Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified. The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to 21 days). Famotidine was well tolerated. All patients reported marked improvements of disease-related symptoms after starting Famotidine. The combined symptom score improved significantly within 24 hours of starting Famotidine and peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased. Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19. A blinded outpatient trial is planned. The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19. Citation Format: Tobias Janowitz, Eva C. Gablenz, David J. Pattinson, Timothy C. Wang, Joseph Conigliaro, Kevin J. Tracey, David A. Tuveson. Famotidine use and quantitative symptom tracking for COVID-19 in nonhospitalized patients: A case series [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr S04-01.

  • Famotidine use and quantitative symptom tracking for covid 19 in non hospitalised patients a case series
    Gut, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist Famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient reported outcome measures in non-hospitalised patients with COVID-19 who self-administered high-dose Famotidine orally. Design Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, Famotidine use, drug-related side effects, temperature measurements, oxygen saturations and symptom scores were obtained using questionnaires and telephone interviews. Based on a National Institute of Health (NIH)-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches and anosmia) and general unwellness on a four-point ordinal scale modelled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalised symptom scores were statistically compared. Results Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified. The most frequently used Famotidine regimen was 80 mg three times daily (n=6) for a median of 11 days (range: 5–21 days). Famotidine was well tolerated. All patients reported marked improvements of disease related symptoms after starting Famotidine. The combined symptom score improved significantly within 24 hours of starting Famotidine and peripheral oxygen saturation (n=2) and device recorded activity (n=1) increased. Conclusions The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.

  • Famotidine use and quantitative symptom tracking for covid 19 in nonhospitalized patients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reducemorbidity, mortality, and spread of the disease are an urgent global need The over-the-counter histamine-2 receptorantagonist Famotidine is a putative therapy for COVID-19 We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidineorally Design: Patients were enrolled consecutively after signing written informed consent Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews Based on an NIH-endorsedProtocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms(cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scalemodeled on performance status scoring All data are reported at the patient level Longitudinal combined normalizedsymptom scores were statistically compared Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to21 days) Famotidine was well tolerated All patients reported marked improvements of disease-related symptomsafter starting Famotidine The combined symptom score improved significantly within 24 hours of starting Famotidineand peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19 A blinded outpatient trial isplanned The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19

  • Famotidine use and quantitativesymptom tracking for covid 19 in nonhospitalizedpatients a case series
    Clinical Cancer Research, 2020
    Co-Authors: Tobias Janowitz, Eva C Gablenz, David Pattinson, Timothy C Wang, Joseph Conigliaro, Kevin J Tracey, David A Tuveson
    Abstract:

    Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reducemorbidity, mortality, and spread of the disease are an urgent global need The over-the-counter histamine-2 receptorantagonist Famotidine is a putative therapy for COVID-19 We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose Famotidineorally Design: Patients were enrolled consecutively after signing written informed consent Data on demographics, COVID-19 diagnosis, Famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews Based on an NIH-endorsedProtocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms(cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scalemodeled on performance status scoring All data are reported at the patient level Longitudinal combined normalizedsymptom scores were statistically compared Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral Famotidine were identified The most frequently used Famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to21 days) Famotidine was well tolerated All patients reported marked improvements of disease-related symptomsafter starting Famotidine The combined symptom score improved significantly within 24 hours of starting Famotidineand peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased Conclusions: The results of this case series suggest that high-dose oral Famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19 A blinded outpatient trial isplanned The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19

Related terms

Famotidine - 15 days free trial to Access Experts & Abstracts